{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-22-000021","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2022-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.977474+00:00","generated_at":"2026-06-26T03:11:27.376668+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bio-Rad Q1 revenue $700.1M (-3.7% YoY); core ex-COVID up 6.5%; non-GAAP EPS $4.94 vs $5.21","bullets":["GAAP net loss $3.37B from Sartorius fair value change; non-GAAP net income $149.1M.","Life Science segment sales $347.2M (-5.3% YoY); Clinical Diagnostics $351.8M (-1.9%).","Full-year 2022 outlook: non-GAAP currency-neutral revenue growth ~1-2%; op margin ~19%.","COVID-related revenue fell to ~$45M vs $94M in Q1 2021; core business grew 6.5% currency-neutral.","Management notes macro risks: China lockdowns, Ukraine war, supply chain."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-22-000021","json":"https://secwatch.observer/filing/0000012208-22-000021.json","markdown":"https://secwatch.observer/filing/0000012208-22-000021.md","text":"https://secwatch.observer/filing/0000012208-22-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220822000021/0000012208-22-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220822000021/bio-20220428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T03:11:27.376668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}